Last reviewed · How we verify
TJ107
At a glance
| Generic name | TJ107 |
|---|---|
| Sponsor | TJ Biopharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma (PHASE2)
- NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery (PHASE1)
- Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors (PHASE1, PHASE2)
- Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors (PHASE2)
- A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) (PHASE2)
- Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19 (PHASE1)
- A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TJ107 CI brief — competitive landscape report
- TJ107 updates RSS · CI watch RSS
- TJ Biopharma Co., Ltd. portfolio CI